Skip to content

Development and Clinical Application of Novel Molecular Targeting Probe for bladder cancer

Development and Clinical Application of Nectin4 Nanoantibody ICG Molecular Targeting Probe for bladder cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092677
Enrollment
Unknown
Registered
2024-11-21
Start date
2024-11-25
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder diseases

Interventions

Gold Standard:Pathological examination results of the sample
Index test:Pathological examination results of the sample area indicated by the probe

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Patients clinically diagnosed with bladder masses requiring cystoscopy, specifically: 1) recurrent surgical hematuria of unknown cause; 2) The patient's B-ultrasound or CT scan suggests a bladder mass; 3) The patient's physical examination requires a cystoscopy examination. (2) Both males and females over the age of 18 are eligible, with no clear contraindications for cystoscopy. (3) The patient is willing to undergo cystoscopy examination. (4) Through preoperative communication, patients and their families expressed full knowledge of their condition and the choice of cystoscopy examination plan, and signed informed consent and informed choice forms. Note: Simultaneously meet the above standards.

Exclusion criteria

Exclusion criteria: (1) Patients who refuse surgical treatment or explicitly refuse to participate in this clinical study; (2) Patients with contraindications for anesthesia or cystoscopy, such as decompensation of underlying cardiovascular and pulmonary diseases, and a tendency towards severe bleeding. Note: Meeting any of the above criteria is sufficient.

Design outcomes

Primary

MeasureTime frame
Probe fluorescence intensity;

Countries

China

Contacts

Public ContactHe yuhui

China-Japan Friendship Hospital

byhyh2016@163.com+86 131 2139 1766

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026